LSVT-BIG Improves UPDRS III Scores at 4 Weeks in Parkinson’s Disease Patients with Wearing Off: A Prospective, Open-Label Study

Table 1

Clinical characteristics of patients with Parkinson’s disease.

Patients	Age (years)	Sex	Hoehn and Yahr	Disease duration (years)	Daily off time (hours)	UPDRS-III	Medication (daily dose)
1	61	F	3	11	3.2	14	L/C 400 mg, ROP 12 mg, AMA 150 mg
2	66	F	3	13	5	13	L/C 650 mg, PRA 1.5 mg, AMA 300 mg, SEL 2.5 mg
3	58	F	2.5	8	3.2	20	L/C 300 mg, CAB 3 mg, AMA 150 mg
4	72	M	2	11	5.2	0	L/B 700 mg, ENT 600 mg, PRA-CR 4.5 mg, PER 750 μg, SEL 5 mg, ZON 25 mg, IST 20 mg
5	53	M	2	13	5.2	8	L/C 600 mg, CAB 2 mg, AMA 150 mg, ZON 25 mg, IST 40 mg, TRI 6 mg
6	71	F	2	8	6	12	L/C 600 mg, PRA 1.5 mg, AMA 150 mg, IST 20 mg
7	69	M	3	24	4.8	9	L/C 350 mg, PER 1500 μg, ENT 300 mg, AMA 100 mg, ZON 25 mg, IST 40 mg
8	56	F	3	14	4.9	26	L/C 1000 mg, PRA-CR 4.5 mg, AMA 300 mg, ZON 50 mg, TRI 3 mg

L/C, levodopa/carbidopa; L/B, levodopa/benserazide; PRA, pramipexole; PRA-CR, pramipexole continuous release; ROP, ropinirole; CAB, cabergoline; AMA, amantadine; SEL, selegiline; ENT, entacapone; ZON, zonisamide; IST, istradefylline; TRI, trihexyphenidyl; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III.